The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.

Abstract / Summary

Capacitive hyperthermia (cHT) has been established for superficial tumors but the efficacy of cHT for intermediate or deep-seated tumors remains a subject of debate. This review is an evaluation of the current clinical evidence on the effectiveness of cHT in the treatment of tumors that are located deeper within the body. A systematic review was conducted in accordance with the PRISMA guidelines of Phase III randomized controlled trials that included cancer patients of all ages and sexes with confirmed malignant tumors undergoing radiotherapy (RT) and/or chemotherapy (CT), with or without additional cHT. The literature search was conducted in PubMed and the Cochrane Register of Controlled Trials (CENTRAL). The primary endpoints included overall survival (OS), tumor response (TR; encompassing complete response (CR)), local control (LC), and cHT treatment-related toxicity (TRT). A total of nine randomized phase III trials were included in the study. The combination of cHT with RT and/or CT was found to improve both LC and OS in three out of five trials conducted in patients with cervical cancer. The analysis of both head and neck cancer trials demonstrated a marked increase in TR rates in cases where cHT was employed. Conversely, no such benefit was observed in non-small cell lung cancers and in a large multicenter cervical cancer trial. The treatment was well tolerated, with mild to moderate adverse events being the most common. It has been demonstrated that the combination of cHT with either RT or CT may improve TR and LC and, in certain cases, OS when compared with RT with or without CT alone. The occurrence of significant side effects is rare.

Related Clinical Guidelines